{"drugs":["Olysio","Simeprevir"],"mono":{"0":{"id":"930835-s-0","title":"Generic Names","mono":"Simeprevir"},"1":{"id":"930835-s-1","title":"Dosing and Indications","sub":[{"id":"930835-s-1-4","title":"Adult Dosing","mono":"<ul><li>Baseline screening for presence of virus with NS3 Q80K polymorphism strongly recommended prior to initiating treatment with simeprevir in combination with peginterferon alfa and ribavirin; if present, consider alternative therapy. Screening may also be considered when used in combination with sofosbuvir.<\/li><li><b>Hepatitis C, chronic, Genotype 1, in combination with other hepatitis C antivirals:<\/b> Combination therapy with peginterferon alfa and ribavirin, 150 mg ORALLY once daily for 12 weeks plus peginterferon alfa and ribavirin for an additional 12 weeks for treatment-naive patients or patients with prior relapse; continue peginterferon alfa and ribavirin for an additional 36 weeks for patients with prior treatment failure; continued treatment with peginterferon alfa and ribavirin is based on clinical response; discontinue 3-drug regimen at treatment week 4 if viral RNA levels are 25 international units\/mL or greater; discontinue peginterferon alfa\/ribavirin therapy at week 12 or 24 if viral RNA levels are 25 international units\/mL or greater<\/li><li><b>Hepatitis C, chronic, Genotype 1, in combination with other hepatitis C antivirals:<\/b> Combination therapy with sofosbuvir, 150 mg ORALLY once daily for 12 weeks in patients without cirrhosis or 24 weeks in patients with cirrhosis, regardless of previous interferon-based therapy<\/li><\/ul>"},{"id":"930835-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in pediatric patients "},{"id":"930835-s-1-6","title":"Dose Adjustments","mono":"<ul><li>To prevent treatment failure, dosage reduction or interruption of simeprevir is not recommended.<\/li><li>If concomitant antiviral therapy is discontinued, simeprevir must be discontinued.<\/li><li><b>Renal impairment:<\/b> No adjustment required in mild, moderate, or severe impairment<\/li><li><b>Hepatic impairment, mild (Child-Pugh class A):<\/b> No adjustment required<\/li><li><b>Hepatic impairment, moderate or severe (Child-Pugh class B or C):<\/b> Use not recommended; when used concomitantly with peginterferon alfa and ribavirin, use is contraindicated in decompensated cirrhosis (moderate or severe hepatic impairment).<\/li><li><b>Geriatric:<\/b> No adjustment required.<\/li><li><b>Dialysis:<\/b> Unlikely to result in significant removal of simeprevir<\/li><li><b>East Asian ancestry:<\/b> No recommendations available<\/li><\/ul>"},{"id":"930835-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hepatitis C, chronic, Genotype 1, in combination with other hepatitis C antivirals<br\/>"}]},"3":{"id":"930835-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930835-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"930835-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Symptomatic bradycardia has been reported when amiodarone is used concomitantly with sofosbuvir in combination with other direct acting antivirals, including simeprevir; some cases have required pacemaker intervention and one case involved fatal cardiac arrest; this risk is increased with underlying cardiac comorbidities, advanced liver disease, and concomitant beta blocker use; monitoring recommended; discontinuation may be required<\/li><li>Dermatologic:<\/li><li>-- Photosensitivity reactions, including those resulting in hospitalization, have been reported with use in combination with peginterferon alfa and ribavirin; discontinuation may be necessary and monitor until resolution<\/li><li>-- Rash, sometimes severe, has been reported with use in combination with peginterferon alfa and ribavirin; monitor mild to moderate rash for progression, discontinue use if severe rash occurs, and monitor until resolution<\/li><li>Hepatic:<\/li><li>-- Hepatic decompensation and failure has been reported, mostly in patients with current advanced or decompensated cirrhosis; monitoring recommended<\/li><li>-- Moderate or severe hepatic impairment; not recommended<\/li><li>-- Bilirubin level increases, not impacting hepatic function, have been reported; monitoring recommended; discontinue if accompanied by liver transaminase increases or signs or symptoms of hepatic decompensation<\/li><li>Immunologic:<\/li><li>-- Sulfa allergy; contains sulfonamide moiety<\/li><li>Other:<\/li><li>-- Do not use as monotherapy<\/li><li>-- Increased risk of adverse reactions (eg, rash and photosensitivity) has been reported in patients with East Asian ancestry<\/li><li>Concomitant use:<\/li><li>-- Combination therapy with amiodarone and sofosbuvir is not recommended<\/li><li>-- Use with moderate or strong CYP3A inducers or inhibitors not recommended<\/li><\/ul>"},{"id":"930835-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930835-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930835-s-4","title":"Drug Interactions","sub":[{"id":"930835-s-4-13","title":"Contraindicated","mono":"<ul>Colchicine (theoretical)<\/ul>"},{"id":"930835-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Aliskiren (theoretical)<\/li><li>Ambrisentan (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amprenavir (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Atorvastatin (established)<\/li><li>Boceprevir (theoretical)<\/li><li>Bosentan (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Digoxin (established)<\/li><li>Diltiazem (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Efavirenz (established)<\/li><li>Eliglustat (theoretical)<\/li><li>Erythromycin (established)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Ezetimibe (theoretical)<\/li><li>Fexofenadine (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Irinotecan (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Ledipasvir (established)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Loperamide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Methotrexate (theoretical)<\/li><li>Mexiletine (theoretical)<\/li><li>Miconazole (theoretical)<\/li><li>Midazolam (established)<\/li><li>Mifepristone (theoretical)<\/li><li>Milk Thistle (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Modafinil (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Nafcillin (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Netupitant (theoretical)<\/li><li>Nevirapine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Olmesartan (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Propranolol (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Repaglinide (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Ritonavir (established)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Rosuvastatin (established)<\/li><li>Saquinavir (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sildenafil (theoretical)<\/li><li>Silodosin (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simvastatin (established)<\/li><li>Sirolimus (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Tadalafil (theoretical)<\/li><li>Talinolol (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Triazolam (theoretical)<\/li><li>Valsartan (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Vinblastine (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}]},"5":{"id":"930835-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus (With sofosbuvir, 11%; with peginterferon alfa and riboflavin, 22%), Rash (With sofosbuvir, 11%; with peginterferon alfa and ribavirin, 28%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (21% to 22%)<\/li><li><b>Hepatic:<\/b>Hyperbilirubinemia (Grade 1, 27%; grade 2, 18%; grade 3, 4%; grade 4, less than 1%)<\/li><li><b>Neurologic:<\/b>Headache (21%), Insomnia (14%)<\/li><li><b>Other:<\/b>Fatigue (25%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Photosensitivity (5% to 7%), Rash (Grade 3, 1%)<\/li><li><b>Hepatic:<\/b>Liver failure<\/li><\/ul>"},"6":{"id":"930835-s-6","title":"Drug Name Info","sub":{"0":{"id":"930835-s-6-17","title":"US Trade Names","mono":"Olysio<br\/>"},"2":{"id":"930835-s-6-19","title":"Class","mono":"<ul><li>Antiviral<\/li><li>Protease Inhibitor<\/li><\/ul>"},"3":{"id":"930835-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930835-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930835-s-7","title":"Mechanism Of Action","mono":"Simeprevir inhibits hepatitis C virus (HCV) NS3\/4A protease thus interfering with viral replication. In biochemical assays, the proteolytic activity of recombinant genotype 1a and 1b HCV NS3\/4A proteases were inhibited.<br\/>"},"8":{"id":"930835-s-8","title":"Pharmacokinetics","sub":[{"id":"930835-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 4 to 6 hours<\/li><li>Effect of food: AUC increased by 61% and absorption delayed by 1 hour (high-fat, high-caloric meal); AUC increased by 69% and absorption delayed by 1.5 hours (normal-caloric meal)<\/li><\/ul>"},{"id":"930835-s-8-24","title":"Distribution","mono":"Protein binding: greater than 99.9%, primarily to albumin <br\/>"},{"id":"930835-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: via CYP3A<\/li><li>substrate and mild inhibitor of CYP3A4: mildly inhibits intestinal CYP3A4 activity but does not affect hepatic CYP3A4 activity<\/li><li>substrate and inhibitor of P-glycoprotein<\/li><li>substrate and inhibitor of OATP1B1\/3<\/li><\/ul>"},{"id":"930835-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 91% (31% unchanged)<\/li><li>Renal: 1%<\/li><li>Dialyzable: Unlikely (hemodialysis)<\/li><\/ul>"},{"id":"930835-s-8-27","title":"Elimination Half Life","mono":"10 to 13 hours (subjects without hepatitis C virus [HCV] infection); 41 hours (subjects with HCV infection) <br\/>"}]},"9":{"id":"930835-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Do not interrupt dosing schedule or reduce dose<\/li><li>Swallow whole<\/li><li>Take with food<\/li><li>Give concomitantly with other antiviral drugs; if any other antiviral drug is discontinued for any reason, simeprevir must also be discontinued<\/li><\/ul>"},"10":{"id":"930835-s-10","title":"Monitoring","mono":"<ul><li>Hepatitis C virus (HCV) RNA assay; as clinically indicated and at weeks 4, 12, and 24; use a sensitive assay which has a lower limit of HCV RNA quantification of at least 25 international units\/mL<\/li><li>NS3 Q80K polymorphism screening, in patients with HCV genotype 1a infection; prior to initiating therapy<\/li><li>Liver chemistry tests; before and during therapy, especially in patients who develop a bilirubin level of greater than 2.5 times ULN<\/li><\/ul>"},"11":{"id":"930835-s-11","title":"How Supplied","mono":"<b>Olysio<\/b><br\/>Oral Capsule: 150 MG<br\/>"},"13":{"id":"930835-s-13","title":"Clinical Teaching","mono":"<ul><li>Encourage female patients of childbearing potential to avoid becoming pregnant and to use adequate contraception during treatment.<\/li><li>Advise patient to use sunscreen, wear protective clothing, and avoid sunlight or sunlamps as drug causes photosensitivity.<\/li><li>Tell patient to take appropriate precautions to prevent transmission of hepatitis C infection as effect of drug on transmission is unknown.<\/li><li>Side effects may include pruritus, nausea, myalgia, headache, and fatigue.<\/li><li>Counsel patient to immediately report a rash.<\/li><li>Tell patient to take drug with food to enhance absorption.<\/li><li>Instruct patient to swallow capsules whole.<\/li><li>Advise patient that there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><li>Instruct patient to take a missed dose as soon as possible, but if next dose is in less than 12 hours, skip the missed dose.<\/li><\/ul>"}}}